Compare SMCI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMCI | NBIX |
|---|---|---|
| Founded | 1993 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 17.7B |
| IPO Year | 2006 | 1996 |
| Metric | SMCI | NBIX |
|---|---|---|
| Price | $27.19 | $169.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 28 |
| Target Price | $43.60 | ★ $208.11 |
| AVG Volume (30 Days) | ★ 33.9M | 1.3M |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.05 | 41.95 |
| EPS | 1.75 | ★ 5.26 |
| Revenue | ★ $2,484,929,000.00 | $161,626,000.00 |
| Revenue This Year | $98.72 | $39.52 |
| Revenue Next Year | $11.34 | $14.81 |
| P/E Ratio | ★ $17.30 | $33.11 |
| Revenue Growth | 11.68 | ★ 977.51 |
| 52 Week Low | $19.48 | $122.14 |
| 52 Week High | $51.40 | $186.12 |
| Indicator | SMCI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 70.47 |
| Support Level | $24.98 | $169.01 |
| Resistance Level | $33.54 | $183.65 |
| Average True Range (ATR) | 2.14 | 5.24 |
| MACD | -0.26 | 2.69 |
| Stochastic Oscillator | 15.38 | 89.90 |
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.